EMA Prepares To Deliver Verdict On Bevacizumab In Wet AMD

Opinion Could Be Drug's First OK For Ocular Use

This week could finally see an ophthalmic version of the anticancer drug bevacizumab recommended for use in wet AMD across the EU. Several other new products are also up for a CHMP opinion.

Subcutaneous injection
Bevacizumab is often used off label as an intraocular injection for AMD • Source: Shutterstock

The first product containing bevacizumab intended for the treatment of wet age-related macular degeneration could well be on its way to an EU marketing authorization if the European Medicines Agency gives it the green light this week.

Ophthalmic bevacizumab is up for an opinion from the EMA’s human drugs committee, the CHMP, during its latest monthly

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography